Europe Multicancer Screening Market: Analysis and Forecast, 2023-2032

1.1 Market Scope
1.1.1 Key Questions Answered in the Report
1.2 Research Methodology
1.2.1 Multicancer Screening Market: Research Methodology
1.2.2 Data Sources
1.2.3 Market Estimation Model
1.2.4 Criteria for Company Profiling

2.1 Market Overview
2.2 Multicancer Screening Workflow Analysis
2.3 Market Footprint and Growth Potential
2.4 Future Potential
2.5 COVID-19 Impact on the Market

3.1 Patent Analysis
3.1.1 Patent Filing Trend
3.1.2 Patent Analysis (by Country)
3.1.3 Patent Analysis (by Region)
3.2 Reimbursement Scenario
3.3 Supply Chain Analysis
3.4 Pricing Analysis (by Test Type)

4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
4.4 Market Challenges
4.4.1 Lack of Awareness about the Multicancer Screening Tests
4.4.2 Too Costly to be Used as Preventive Care
4.5 Market Opportunities
4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
4.5.2 New Biomarkers being Discovered Regularly

5.1 Overview
5.2 Europe
5.2.1 Germany
5.2.2 France
5.2.3 U.K.
5.2.4 Italy
5.2.5 Spain
5.2.6 Rest-of-Europe

6.1 Overview
6.2 Market Value Chain of Multicancer Screening Market
6.3 Multicancer Screening Ecosystem Active Players
6.4 F. Hoffmann-La Roche Ltd
6.4.1 Company Overview
6.4.2 Role of F. Hoffmann-La Roche Ltd in the Multicancer Screening Market
6.4.3 Key Competitors of the Company
6.4.4 Financials
6.4.5 Corporate Strategies
6.4.6 Business Strategies
6.4.7 Analyst Perspective

Figure 1: Europe Multicancer Screening Market, $Billion, 2022 and 2032
Figure 2: Share of Multicancer Screening Market (by Region), 2022
Figure 3: Multicancer Screening Market: Research Methodology
Figure 4: Primary Research Methodology
Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
Figure 6: Top-Down Approach (Segment-Wise Analysis)
Figure 7: Multicancer Screening Workflow, End User Perspective
Figure 8: Multicancer Screening Workflow, Laboratory Technician Perspective
Figure 9: Europe Multicancer Screening Market, $Billion, 2021-2032
Figure 10: COVID-19 Impact
Figure 11: Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
Figure 12: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
Figure 13: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
Figure 14: Supply Chain Analysis of the Multicancer Screening Market
Figure 15: Multicancer Screening Market Dynamics
Figure 16: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
Figure 17: Liquid Biopsy vs. Tissue Biopsy
Figure 18: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
Figure 19: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
Figure 20: Lead-Time Bias in Cancer Screening
Figure 21: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
Figure 22: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
Figure 23: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
Figure 24: Multicancer Screening Market (by Region), $Billion, 2021-2032
Figure 25: Europe Multicancer Screening Market, $Billion, 2021-2032
Figure 26: Europe Multicancer Screening Market (by Country), $Million, 2021-2032
Figure 27: Germany Multicancer Screening Market, $Million, 2021-2032
Figure 28: France Multicancer Screening Market, $Million, 2021-2032
Figure 29: U.K. Multicancer Screening Market, $Million, 2021-2032
Figure 30: Italy Multicancer Screening Market, $Million, 2021-2032
Figure 31: Spain Multicancer Screening Market, $Million, 2021-2032
Figure 32: Rest-of-Europe Multicancer Screening Market, $Million, 2021-2032
Figure 33: Multicancer Screening Market, Total Number of Companies Profiled
Figure 34: Multicancer Screening Market: Value Chain
Figure 35: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 36: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 38: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022

Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Multicancer Screening Market
Table 2: Technological Trends in Multicancer Screening Market
Table 3: Average Prices of Multicancer Screening Kits Calculation
Table 4: Likert Scale
Table 5: Impact Analysis of Market Drivers
Table 6: Impact Analysis of Market Challenges
Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
Table 8: Top Multicancer Screening Tests and Their Costs ($)
Table 9: Multicancer Screening Market, Pipeline Tests
Table 10: Cancers and Their Most Common Biomarker Tests